You just read:

MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3 - a Potential New Gold Standard, First-line Treatment for Clostridium difficile Infection (CDI)

News provided by

MGB Biopharma

May 19, 2020, 04:00 ET